![]() ![]() The Treg cell or Treg cell population according to anyone of claims 17 to 20, or the pharmaceutical composition according to claim 21, for use in a method according to claim 23, wherein the individual with the pathological condition is human.Ģ5. The Treg cell or Treg cell population according to anyone of claims 17 to 20, or the pharmaceutical composition according to claim 21, for autologous or allogeneic use in a method for treating and/or preventing a pathological condition selected from the list consisting of: autoimmune disease, inflammatory processes, allergy, graft-versus-host disease and/or immune rejection in transplanted individuals.Ģ4. The Treg cell or Treg cell population according to anyone of claims 17 to 20, or the pharmaceutical composition according to claim 21, for use as a medicament.Ģ3. A pharmaceutical composition comprising the Treg cell or the Treg cell population, according to anyone of claims 17 to 20, wherein said pharmaceutical composition further comprises an excipient and/or pharmaceutically acceptable carrier.Ģ2. The Treg cell or Treg cell population, according to claim 19, wherein the antigen is an antigen present in an effector cell of the immune system.Ģ1. The Treg cell or Treg cell population, according to claim 18, wherein said cell comprises a nucleic acid sequence encoding a chimeric antigen receptor.Ģ0. The Treg cell or Treg cell population, according to claim 17, wherein said cell has been genetically modified.ġ9. A regulatory T (Treg) cell or Treg cell population obtained by the method, according to anyone of claims 1 to 16.ġ8. The method, according to anyone of claims 1 to 15, which further comprises an additional step (g) comprising the cryopreservation of the regulatory T cells obtained.ġ7. ![]() The method, according to anyone of claims 1 to 14, wherein the thymic tissue comes from a human between 0 and 16 years old, preferably from a human between 0 and 24 months old.ġ6. The method, according to anyone of claims 1 to 13, wherein the thymic tissue comes from a human.ġ5. The method according to anyone of claims 1 to 12, wherein the obtained Treg cell population comprises at least 80%, preferably at least 85%, more preferably at least 90% of CD4+, CD25+ and Foxp3+ cells.ġ4. The method according to anyone of claims 1 to 11, wherein said culture medium further comprises antibiotic, preferably 5% of antibiotic.ġ3. The method according to anyone of claims 1 to 10, wherein said culture medium is a GMP culture medium.ġ2. The method, according to anyone of claims 1 to 9, wherein the cells are cultured in step f) in the absence of rapamycin.ġ1. The method according to anyone of claims 1 to 8, wherein in step f) the regulatory T cells are cultured for another one to seven days, preferably for another four days in the presence of IL-2.ġ0. The method according to anyone of claims 1 to 7, wherein the removal of stage (e) is carried out by means of centrifugation.ĩ. The method, according to anyone of claims 1 to 6, wherein the cells are cultured in step (d) in the absence of rapamycin.Ĩ. The method according to anyone of claims 1 to 5, wherein the cells are cultured in step (d) for at least 2 or 3 days, preferably for at least 3 days.ħ. Texmacs gmp medium Activator#The method according to anyone of claims 1 to 4, wherein the T cell activator of stage (d) is a colloidal polymer nanomatrix conjugated with humanised CD3 and CD28 agonists.Ħ. The method according to anyone of claims 1 to 3, wherein the T cell activator of stage (d) comprises CD3 and CD28 agonists.ĥ. ![]() ![]() The method according to anyone of claim 1 or 2, wherein isolation of CD25+ cells in step c) comprises the use of magnetic beads conjugated to antibodies against CD25.Ĥ. The method according to claim 1, wherein step a) comprises mechanically disaggregating the thymic tissue in the presence of a culture medium and without using enzymes.ģ. optionally, further culturing the regulatory T cells in a culture medium in the presence of IL-2 with the proviso that prior to step (d) the cell population has not been depleted from CD8+ cells.Ģ. removing the T cell activator from the culture medium of stage (d) f. culturing the cell population obtained after stage (c) in a culture medium in the presence of a T cell activator and IL-2, preferably wherein said T cell activator comprises at least CD3 and CD28 agonists and e. isolating CD25+ cells from the product obtained after stage (b) d. filtering the product obtained after stage (a), and resuspending the precipitate comprising thymocytes in a culture medium c. mechanically disaggregating the thymic tissue b. An in vitro method for obtaining a regulatory T (Treg) cell population from isolated thymic tissue comprising the following steps: a. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |